Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Canadian Overseas Petroleum Limited (V9L.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.0330+0.0135 (+69.2308%)
https://finance.yahoo.com/quote/V9L.F?p=V9L.F&.tsrc=fin-srch
BAE reported profits of £1.23bn this morning and upped its dividend by 11 per cent year-on-year, as it continued to cash in on increased UK defence spending and soaring demand amid the war in Ukraine.
Britain’s premier defence contractor saw an order intake of £21.1bn, resulting in a record order backlog of £66.2bn. Revenues also shot up 11 per cent to £11bn, with top line sales growing by just under £1.5bn to £12bn year-on-year.
As a result, the firm – who manufacture submarines and fighter jets and a slew of other military vehicles – upgraded its guidance for 2023, forecasting higher sales and earnings per share of between 10 to 12 per cent, which it said reflected higher profits.
Charles Woodburn, BAE Systems Chief Executive, said: “We’ve delivered a strong financial performance in the first half of the year, thanks to the outstanding efforts of our employees.”
“With a record order backlog and good operational performance, we’re well positioned to continue delivering sustained growth in the coming years, giving us confidence to continue investing in new technologies, facilities, highly-skilled jobs and in our local communities.”
BAE said it had benefited from an “elevated global threat environment,” as Russia’s War in Ukraine and rising geopolitical uncertainty bumps up demand for weapons and defence systems.
Ascendant demand amid Putin’s war has ricocheted across the sector as a whole, with competitor Rolls-Royce seeing shares skyrocket 20 per cent last week after it doubled its profit guidance.
But the invasion of Ukraine has prompted not just a rise in demand, but also a shift in focus from the UK government, with many analysts forecasting a move to more production of weapons on home soil – to the benefit of companies’ like BAE.
That view is not without merit, based on the slew of recent lucrative contracts BAE have been awarded by the MoD.
Last month, the government handed BAE a £280m contract to boost the production of howitzer shells from UK factories.
In June, the company received a £270 million contract to manufacture radars for the Royal Navy, creating 400 high-skilled British jobs in the process.
https://www.cityam.com/war-what-is-it-good-for-bae-systems-announces-bumper-dividend/?utm_source=CityAM&utm_campaign=8cf2a6caa6-EMAIL_CAMPAIGN_2023_08_02_06_25&utm_medium=email&utm_term=0_-8cf2a6caa6-%5BLIST_EMAIL_ID%5D
Hares in Newcrest Mining sunk 4.9 per cent on Friday morning after poor earnings reported by takeover bidder Newmont Corporation left analysts wanting.
Newcrest shares were trading at $26.26 each as at 10:17am after Newmont, which is taking over the Australian miner in a transaction valued at $29 billion, reported earnings that missed analyst estimates following a series of operational setbacks.
Its shares fell 6 per cent in New York for the biggest daily decline since July 2022.
Newmont’s second-quarter gold production dropped 17 per cent from a year earlier after it suspended the large Penasquito mine in Mexico due to a workers’ strike and reported weaker-than-expected performances from its Cerro Negro mine in Argentina and Akyem mine in Ghana.
It also temporarily shuttered a mine in Canada because of nearby wildfires.
Overall production costs rose to $1,472 an ounce, exceeding the average analyst estimate compiled by Bloomberg.
Shares in Newmont, which is working to close its acquisition of Newcrest Mining in the industry’s largest-ever deal, have tumbled 10 per cent this year, even as spot gold prices are up about 8 per cent.
The company reiterated its full-year forecasts on Thursday and said it expects a stronger second half.
https://thewest-com-au.cdn.ampproject.org/v/s/thewest.com.au/business/mining/newcrest-mining-shares-take-a-beating-as-newmont-corporation-shares-head-for-biggest-drop-in-a-year--c-11343304.amp?amp_gsa=1&_js_v=a9&usqp=mq331AQGsAEggAID#amp_tf=From%20%251%24s&aoh=16900015030936&csi=0&referrer=https%3A%2F%2Fwww.google.com&share=https%3A%2F%2Fthewest.com.au%2Fbusiness%2Fmining%2Fnewcrest-mining-shares-take-a-beating-as-newmont-corporation-shares-head-for-biggest-drop-in-a-year--c-11343304
Futura has made a new product that works, and it is only just starting to shout about it.
The company’s Eroxon gel is the first erectile dysfunction product approved to go on sale without a prescription. It is already available at Boots and online via the likes of Amazon, and it is the first new ED treatment for two decades. Clinical trials showed Eroxon successfully pumped up 65 per cent of users. Given the scale of the stigma-ridden, $3 billion (£2.3 billion) global market for men suffering a lack of erections — it is forecast to surpass $6 billion by 2032 — Futura looks appealing.
Rival treatments, such as Viagra and Cialis, both need a prescription and take longer to work: the Eroxon gel acts in ten minutes; it’s half an hour with rivals.
Futura has also minimised risk by outsourcing all it can: it does the science, but then, said chief executive James Barder, looks for “commercial partners to do the rest” — the marketing and distribution. “We’ve done so in the UK, Europe, and seven countries in the Middle East. Saudi [Arabia’s] approval is expected in September — that’s the biggest erectile dysfunction market in the Middle East — and we are working on a US partner .”
America has the world’s highest number of ED sufferers by far, and Barder said Futura had “interest from a number of parties”. Signing a commercial deal there would be likely to trigger a share price surge.
“The announcement of that US partner will be crucial as it’s very early days for Eroxon,” said Seb Jantet, an analyst at house broker Liberum. “But there are early signs of success.”
In the UK, where Futura’s product first hit Boots’s shelves exclusively in April, almost £2 million worth of Eroxon was sold in the first eight weeks, the firm told capital market day attendees last month. Its launch partner said it had been one of its most successful over-the-counter launches.
Futura is anticipating sales of £3 million this year — stocking orders from the small markets of the UK and Belgium. “These don’t really show the scale of what the product could do,” Jantet added. But Futura has more than £4 million in cash and a strong balance sheet. There are no guarantees of a happy ending, but it’s a worthy punt. Buy.
https://www.thetimes.co.uk/article/futura-is-looking-for-rapid-growth-8gpml9kzq
7:02 PM BST, July 5, 2023:
HARARE, Zimbabwe (AP) — A Chinese mining company formally opened a $300 million lithium processing plant Wednesday in Zimbabwe, which has one of the world’s largest reserves of the metal as demand surges globally because of its use in electric car batteries.
Zimbabwe has the largest lithium reserves in Africa and has in recent years drawn investors in battery minerals from Canada, the United Kingdom and Australia, although China is the dominant player.
The plant opened by Prospect Lithium Zimbabwe, an arm of Chinese company Zhejiang Huayou Cobalt, has a capacity to process 4.5 million metric tons of hard rock lithium into concentrate for export per year, Zimbabwe President Emmerson Mnangagwa said.
Mnangagwa was present for the official opening of the sprawling plant in Goromonzi, about 80 kilometers (50 miles) southeast of Zimbabwe’s capital, Harare.
“Lithium is the mineral of the present and the future ... and value addition will position our country as an emerging and competitive player in the global lithium value chain,” Mnangagwa said. He urged the company to “beef” up expertise that would help Zimbabwe and other southern African countries “eventually” manufacture lithium batteries and other components locally.
Lithium is a key component for electric vehicle batteries. To cash in on demand, Zimbabwe last year banned the export of raw lithium ore. In doing so, it joined countries like Indonesia and Chile that are trying to maximize their return on deposits of lithium, cobalt and nickel by requiring miners to invest locally in refining and processing before they can export.
Prospect Lithium Zimbabwe deputy general manager Trevor Barnard said that the firm aims to start by processing 450,000 tons of concentrate every year. The concentrate will be further processed into battery-grade lithium outside Zimbabwe.
https://apnews.com/article/lithium-processing-plant-chinese-92ccd10bd4ba028bc38fdadcdffc06da
The changes feed into MGC Pharmaceuticals’ goal to become a significant player in the pioneering field of psychedelic research and development. This aim was further strengthened when, on April this year, the company received approval from the Slovenian Ministry of Health for scientific research developments related to Psilocybin.
As a result of these regulatory advancements, MGC can now provide accurate, pharmaceutical-grade products, reinforcing its commitment to meeting stringent industry standards. Furthermore, the company intends to leverage its existing distribution channels to increase Psilocybin sales in Australia, aiming to provide this treatment option to patients in need.
A friend has passed this on to me and, although I don't endorse it in any way, I post it here as a caution.
Perhaps those more in-the-know than I could verify it:
Premier accounts are due by tomorrow (June 30) and given the claim by Canmax it seems impossible that an auditor will be able to sign off a going concern statement, which in turn will delay the issuing of these accounts and will lead to the shares being suspended.
That could get very messy if it dragged on for any length of time and the likes of Spreadex decided to increase its margin requirements, as they sometimes do for suspended shares.
Mon, 19th Jun 2023 10:16
(Sharecast News) - Oncology drug developer Avacta Group responded to recent market speculation over a potential fundraising initiative on Monday.
The AIM-traded company said it regularly evaluates various funding opportunities, both dilutive and non-dilutive, to ensure the continued financial stability of its business operations while safeguarding the interests of stakeholders.
In line with that strategy, the firm said it engages in ongoing discussions with existing shareholders and potential investors.
HOWEVER, AVACTA CLARIFIED THAT THERE WERE CURRENTLY NO IMMEDIATE PLANS FOR A FUNDRAISING CAMPAIGN
From today's Times:
Inspiration Healthcare’s share price chart would bring doctors running if it flashed up on monitors in the hospitals where its intensive care products are used. From 68p in 2020, the firm, which specialises in neonatal medical machines and aids, saw its stock more than double in the following 12 months before crashing back down to 84p over distribution issues in China last November and halving again to 45p now.
It’s either an ideal time to snap up a bargain in this Crawley-based medtech distributor — or it’s a dud that was overvalued in the Covid years, when its ventilators saw high demand from the NHS. Which is correct?
Inspiration was founded in 2003, and listed on Aim in 2015 via a reverse takeover of Inditherm, which specialises in technology that warms up very sick patients. Today, Inspiration’s key products include the all-in-one SLE6000 ventilator, non-invasive ventilators for babies and cerebral function monitoring systems; the firm sells its own UK-made products in 75 countries, generating 60 per cent of profits from overseas. Its neonatal market specialism is seeing growing demand: more than 15 million babies are born prematurely every year, but that figure is rising worldwide. The neonatal intensive care market is worth $6.8 billion and set to approach $10 billion by 2027, according to analysts ResearchandMarkets.com.
Yet Inspiration’s own trends have not reflected that opportunity. Results for the year to February were muted, with revenues almost flat at £41 million and underlying earnings falling from £6 million a year earlier to £4 million. Chief executive Neil Campbell said the firm had shown “resilience”, a barrel-scraper of a verdict.
There are reasons for cheer: Inspiration invested in a new manufacturing and technology centre in Croydon, increasing both its capacity and capability. It has reliable, high-quality customers, and revenues picked up in the fourth quarter of its last financial year, and amounted to almost £2 million cash in the first two months of its 2024 year. Its policy of investing about 9per cent of sales into R&D should gradually pay off.
Seb Jantet, analyst at house broker Liberum, is realistic: “the recent track record and poor cash generation warrant some caution,” he says, but names a punchy 100p target price because “Inspiration’s core offering is sound and … we expect the discount to peers to close.”
The price to earnings ratio is 9.6 for 2023, down from over 12 last year. Inspiration is a dicey investment, but its medical technology’s time has come: buy.
An Aim-listed drugs company has received US marketing approval for its erectile dysfunction treatment, sending shares sharply higher.
Futura Medical said the US Food and Drug Administration had authorised the sale of Eroxon gel over the counter. The firm said it could be marketed as the first topical treatment for the problem without the need for a prescription.
Shares in Futura Medical closed up 12.4 per cent at 48¼p, valuing the company at £124 million on the London Stock Exchange’s junior market.
The authorisation came after regulators asked for more information from the company, which submitted its application in October. Eroxon has previously received marketing approval in Europe and the Middle East and was launched in the UK in April through a distribution partner.
It is marketed as a clinically proven treatment that “helps you get an erection within ten minutes” compared with oral medications such as Viagra, which Futura said require a doctor’s prescription in America and “typically are required to be taken at least 30 minutes in advance”.
Futura Medical was founded in 2001 and is based in Guildford. Its chairman is John Clarke, 74, a former president of GSK’s consumer healthcare business.
James Barder, 63, Futura Medical’s chief executive, said US marketing approval was a “huge milestone” following the submission of 22 clinical studies and performance bench tests to the regulator. “The FDA set a very high standard in evaluating the effectiveness and safety,” he said, adding that the “approval is a major de-risking event for the company and we look forward to updating shareholders on our US commercialisation plans”.
Analysts at Liberum, which is Futura Medical’s nominated adviser, have said that Eroxon “has the potential to become a global name”.
Liberum said yesterday that the product could “take a significant market share” in America and increased its target price for the company from 121p to 142p, adding: “The next catalyst will be June’s capital markets day and Futura announcing a US market partner, hopefully before the end of 2023.”
Futura Medical said in its full-year results in April that its “cash runway” extends beyond the initial launches expected over the next year and that it had cash resources of £4 million.
Following the FDA authorisation, £4.4 million of warrants were subscribed for, extending the company’s cash visibility to 2025.
Futura Medical had made a net loss of £5.9 million in the year to the end of December, of which £4.1 million related to research and development.